Y Intercept Hong Kong Ltd Has $333,000 Stock Holdings in Establishment Labs Holdings Inc. $ESTA

Y Intercept Hong Kong Ltd decreased its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 83.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,864 shares of the company’s stock after selling 30,178 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Establishment Labs were worth $333,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Goldman Sachs Group Inc. raised its holdings in Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after acquiring an additional 438,206 shares in the last quarter. Viking Global Investors LP bought a new position in Establishment Labs in the second quarter valued at approximately $14,669,000. Soleus Capital Management L.P. bought a new position in Establishment Labs in the second quarter valued at approximately $9,050,000. Summit Partners Public Asset Management LLC grew its stake in Establishment Labs by 87.1% in the third quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock valued at $17,632,000 after purchasing an additional 200,255 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its position in shares of Establishment Labs by 11.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock worth $80,893,000 after purchasing an additional 197,962 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Trading Down 1.5%

ESTA stock opened at $86.59 on Wednesday. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The company has a fifty day moving average price of $79.01 and a two-hundred day moving average price of $71.62. Establishment Labs Holdings Inc. has a one year low of $33.35 and a one year high of $92.83. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -58.11 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The company had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. Establishment Labs’s revenue for the quarter was up 44.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.70) earnings per share. Equities analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. BTIG Research reissued a “buy” rating on shares of Establishment Labs in a research note on Monday. Citigroup boosted their target price on shares of Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Finally, Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.71.

Insider Activity at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 255,000 shares of company stock worth $18,144,896. Insiders own 9.99% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.